Michele Del Vecchio

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Michael A. Davies, Philippe Saïag, Caroline Robert et al. · The Lancet Oncology · 2017 · 759 citations · Full text

Medicine, Melanoma, Pathology +5

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà et al. · The Lancet Oncology · 2020 · 505 citations

Checkmate 238, Surgical Oncology, Medicine +11

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert et al. · The Lancet Oncology · 2017 · 483 citations

Medicine, Melanoma, Ipilimumab 10 +8

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto et al. · The Lancet Oncology · 2017 · 482 citations · Full text

Oncology, Binimetinib Versus Dacarbazine, Medicine +7